Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT04631601
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California at Irvine Medical Center, Orange, California, United States
🇺🇸University of California San Francisco Mission Bay Campus, San Francisco, California, United States
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 54
- Registration Number
- NCT04471974
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Chicago, Evergreen Park, Illinois, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Ricardo Pereira Mestre
- Target Recruit Count
- 7
- Registration Number
- NCT04456049
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 61
- Registration Number
- NCT04455750
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 575
- Registration Number
- NCT04446117
- Locations
- 🇺🇸
Exelixis Clinical Site #6, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #18, Philadelphia, Pennsylvania, United States
🇵🇱Exelixis Clinical Site #243, Otwock, Mazowieckie, Poland
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 162
- Registration Number
- NCT04419402
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Calvary Mater Newcastle, Newcastle, New South Wales, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 74
- Registration Number
- NCT04409288
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04381832
- Locations
- 🇺🇸
Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸The Oncology Institute of Hope & Innovation, Cerritos, California, United States
🇺🇸The University of California, Los Angeles, Encino, California, United States
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
- Conditions
- Interventions
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 150
- Registration Number
- NCT04363164
- Locations
- 🇺🇸
Dana-Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 132
- Registration Number
- NCT04335682
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.